Italy Pulmonary Arterial Hypertension Market Size & Outlook
Italy pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Italy pulmonary arterial hypertension market highlights
- The Italy pulmonary arterial hypertension market generated a revenue of USD 312.7 million in 2023 and is expected to reach USD 441.0 million by 2030.
- The Italy market is expected to grow at a CAGR of 5% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 312.7 million |
| Market revenue in 2030 | USD 441.0 million |
| Growth rate | 5% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Italy accounted for 4.2% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 46.15% in 2023. Horizon Databook has segmented the Italy pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The PAH market in Italy is projected to grow at a moderate rate over the coming years. As per the European Association of Hospital Pharmacy from January1, 2012 to August 31, 2017, an average of 4.83 patients in central Italy were treated with Volibris, Tracleer, Opsumit, Adcirca or Revatio causing higher economic burden on Italy. It was recorded that the prevalence of pulmonary arterial hypertension reported is high compared to Scotland and France.
Moreover, to reduce the economic burden of treatment, centralized procurement at the regional level was incorporated to lower the financial burden. Italy had the largest elderly population in 2019 within the EU. Its growing geriatric population is likely to promote market growth. Key initiatives by market players are expected to further boost the market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Italy Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
